Clinical Trial Update: Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Hepatocellular Carcinoma (HCC) [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating NGR-hTNF as a single agent in patients with advanced or metastatic hepatocellular carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• NGR-hTNF (NGR-hTNF)

Snippet

Sponsor: AGC Biologics S.p.A. | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: COMPLETED